Federal Schedule III reclassification could reshape West Virginia cannabis policy

Potential downscheduling from Schedule I raises questions for state's medical program and emerging legalization efforts.

FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0

A federal reclassification of marijuana to Schedule III—reported by WBOY.com—would alter the regulatory landscape for West Virginia, which currently operates a medical cannabis program that has generated $34 million in revenue but faced spending delays. The shift appears likely to create new federal-state compliance pathways and could accelerate or complicate ongoing state-level policy debates.

West Virginia's cannabis landscape remains in flux: the state House passed expansion of its medical program in March 2026, Democrats have pushed legalization to the ballot, and Gov. Morrisey vetoed a revised $38 million spending bill in April. A Schedule III designation could ease federal banking and research restrictions, potentially unlocking the accumulated medical revenue and affecting whether recreational legalization gains legislative traction.

Key development to watch: whether West Virginia aligns its regulatory framework with the new federal scheduling before the next legislative session, and how any federal rule change influences the gubernatorial and ballot legalization efforts already underway.